TR200301971T4 - Kısmi veya tam A1 agonistler N6 hetorosiklik 5'-Tiyo ikameli adenosin türevleri - Google Patents

Kısmi veya tam A1 agonistler N6 hetorosiklik 5'-Tiyo ikameli adenosin türevleri

Info

Publication number
TR200301971T4
TR200301971T4 TR2003/01971T TR200301971T TR200301971T4 TR 200301971 T4 TR200301971 T4 TR 200301971T4 TR 2003/01971 T TR2003/01971 T TR 2003/01971T TR 200301971 T TR200301971 T TR 200301971T TR 200301971 T4 TR200301971 T4 TR 200301971T4
Authority
TR
Turkey
Prior art keywords
partial
agonists
complete
heterorocyclic
adenosine derivatives
Prior art date
Application number
TR2003/01971T
Other languages
English (en)
Inventor
A. Zablocki Jeff
P. Palle Venkate
Varkhed Kar Vaibhav
Belardinelli Lu�Z
N. Ibrahim Prabha
Original Assignee
Cv Therapeutics, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cv Therapeutics, Inc. filed Critical Cv Therapeutics, Inc.
Publication of TR200301971T4 publication Critical patent/TR200301971T4/tr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/16—Purine radicals
    • C07H19/167—Purine radicals with ribosyl as the saccharide radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/16—Purine radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Obesity (AREA)
  • Neurosurgery (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Endocrinology (AREA)
  • Pain & Pain Management (AREA)
  • Child & Adolescent Psychology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Hospice & Palliative Care (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Saccharide Compounds (AREA)

Abstract

Adenosin A1 reseptörü kismi veya tam agonistleri olan ve bu nedenle memelilerde ve özellikle insanlarda kardiyak aktivitesinin modifiye edilmesi, adiposit fonksiyonun modifiye edilmesi, merkezi sinir sistemi bozukluklarinin tedavisi ve diyabetik bozukluklarin ve obesitenin tedavisi için yararli olan N6 heterosiklik 5' modifikasyonlu adenosin türevleri.
TR2003/01971T 1999-12-03 2000-12-01 Kısmi veya tam A1 agonistler N6 hetorosiklik 5'-Tiyo ikameli adenosin türevleri TR200301971T4 (tr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US09/454,136 US6605597B1 (en) 1999-12-03 1999-12-03 Partial or full A1agonists-N-6 heterocyclic 5′-thio substituted adenosine derivatives

Publications (1)

Publication Number Publication Date
TR200301971T4 true TR200301971T4 (tr) 2004-01-21

Family

ID=23803455

Family Applications (2)

Application Number Title Priority Date Filing Date
TR2001/03129T TR200103129T2 (tr) 1999-12-03 2000-12-01 Kısmi ya da tam A1 agonistleri-N6 heterosiklik 5'-tio ikameli adenosin türevleri.
TR2003/01971T TR200301971T4 (tr) 1999-12-03 2000-12-01 Kısmi veya tam A1 agonistler N6 hetorosiklik 5'-Tiyo ikameli adenosin türevleri

Family Applications Before (1)

Application Number Title Priority Date Filing Date
TR2001/03129T TR200103129T2 (tr) 1999-12-03 2000-12-01 Kısmi ya da tam A1 agonistleri-N6 heterosiklik 5'-tio ikameli adenosin türevleri.

Country Status (25)

Country Link
US (2) US6605597B1 (tr)
EP (1) EP1233973B1 (tr)
JP (1) JP4021195B2 (tr)
KR (1) KR100484988B1 (tr)
CN (1) CN1152042C (tr)
AR (1) AR029199A1 (tr)
AT (1) ATE254133T1 (tr)
AU (3) AU4138701A (tr)
BR (1) BR0016126A (tr)
CA (1) CA2389264C (tr)
CZ (1) CZ20013705A3 (tr)
DE (1) DE60006576T2 (tr)
DK (1) DK1233973T3 (tr)
ES (1) ES2208437T3 (tr)
HK (1) HK1047941A1 (tr)
HU (1) HUP0500455A2 (tr)
IL (1) IL145903A (tr)
MX (1) MXPA01011113A (tr)
NO (1) NO20015373L (tr)
NZ (1) NZ514777A (tr)
PT (1) PT1233973E (tr)
TR (2) TR200103129T2 (tr)
TW (1) TWI249536B (tr)
WO (2) WO2001040243A2 (tr)
ZA (1) ZA200204380B (tr)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
USRE47351E1 (en) 1999-06-22 2019-04-16 Gilead Sciences, Inc. 2-(N-pyrazolo)adenosines with application as adenosine A2A receptor agonists
US6403567B1 (en) * 1999-06-22 2002-06-11 Cv Therapeutics, Inc. N-pyrazole A2A adenosine receptor agonists
US6214807B1 (en) * 1999-06-22 2001-04-10 Cv Therapeutics, Inc. C-pyrazole 2A A receptor agonists
US6605597B1 (en) * 1999-12-03 2003-08-12 Cv Therapeutics, Inc. Partial or full A1agonists-N-6 heterocyclic 5′-thio substituted adenosine derivatives
US20020012946A1 (en) 2000-02-23 2002-01-31 Luiz Belardinelli Method of identifying partial agonists of the A2A receptor
GB2372741A (en) * 2001-03-03 2002-09-04 Univ Leiden C2,8-Disubstituted adenosine derivatives and their different uses
GB2372742A (en) * 2001-03-03 2002-09-04 Univ Leiden C2,5'-Disubstituted and N6,C2,5'-trisubstituted adenosine derivatives and their different uses
US7157440B2 (en) 2001-07-13 2007-01-02 Cv Therapeutics, Inc. Partial and full agonists of A1 adenosine receptors
US6946449B2 (en) 2001-07-13 2005-09-20 Cv Therapeutics, Inc. Partial and full agonists of A1 adenosine receptors
US7713946B2 (en) 2002-07-11 2010-05-11 Cv Therapeutics, Inc. Partial and full agonists A1 adenosine receptors
NZ534801A (en) * 2002-02-19 2006-04-28 Cv Therapeutics Inc Partial and full agonists of A1 adenosine receptors
CN101385738A (zh) * 2002-04-18 2009-03-18 Cv医药有限公司 包括给予A1腺苷激动剂以及β受体阻滞剂、钙通道阻滞剂、或强心苷的治疗心律失常的方法
US8470801B2 (en) 2002-07-29 2013-06-25 Gilead Sciences, Inc. Myocardial perfusion imaging methods and compositions
MXPA05001123A (es) * 2002-07-29 2005-04-29 Cv Therapeutics Inc Formacion de imagenes por perfusion de miocardio mediante el uso de agonistas receptores de a2a.
US20050020915A1 (en) * 2002-07-29 2005-01-27 Cv Therapeutics, Inc. Myocardial perfusion imaging methods and compositions
KR20050097971A (ko) 2003-02-03 2005-10-10 씨브이 쎄러퓨틱스, 인코포레이티드 Ａ₁아데노신 수용체의 부분 및 전 작용제
US7335648B2 (en) 2003-10-21 2008-02-26 Inspire Pharmaceuticals, Inc. Non-nucleotide composition and method for inhibiting platelet aggregation
US7368438B2 (en) 2003-10-21 2008-05-06 Inspire Pharmaceuticals, Inc. Non-nucleotide compositions and method for inhibiting platelet aggregation
WO2005039590A1 (en) 2003-10-21 2005-05-06 Inspire Pharmaceuticals, Inc. Non-nucleotide compositions and method for treating pain
US7749981B2 (en) 2003-10-21 2010-07-06 Inspire Pharmaceuticals, Inc. Drug-eluting stents coated with non-nucleotide P2Y12 receptor antagonist compound
DK1682537T3 (da) 2003-11-05 2012-07-09 Sarcode Bioscience Inc Modulatorer af celleadhæsion
CN101076343A (zh) * 2004-10-20 2007-11-21 Cv医药有限公司 A2a腺苷受体激动剂的应用
US7932376B2 (en) 2005-05-05 2011-04-26 Inspire Pharmaceuticals, Inc. Pyrimidine-based non-nucleotide composition and method for inhibiting platelet aggregation
PL1881823T3 (pl) 2005-05-17 2015-05-29 Sarcode Bioscience Inc Kompozycje i sposoby leczenia chorób oczu
EA015683B1 (ru) * 2005-11-30 2011-10-31 Инотек Фармасьютикалз Корпорейшн Производные пурина и способы их применения
CN102260311A (zh) 2006-02-03 2011-11-30 吉利德帕洛阿尔托股份有限公司 制备一种a2a型腺苷受体激动剂及其多晶形物的方法
EP2021350B1 (en) 2006-03-21 2016-12-21 Rheinische Friedrich-Wilhelms-Universität Bonn Phosphorylated a2a receptor agonists
WO2008063712A1 (en) * 2006-06-22 2008-05-29 Cv Therapeutics, Inc. Use of a2a adenosine receptor agonists in the treatment of ischemia
JP2010502649A (ja) * 2006-09-01 2010-01-28 シーブイ・セラピューティクス・インコーポレイテッド 心筋層画像化法中の患者の耐性を増加させるための方法および組成物
US20090081120A1 (en) * 2006-09-01 2009-03-26 Cv Therapeutics, Inc. Methods and Compositions for Increasing Patient Tolerability During Myocardial Imaging Methods
JP2011502101A (ja) * 2006-09-29 2011-01-20 ギリアード・パロ・アルト・インコーポレイテッド 肺疾患の病歴を有する患者における心筋画像化法
MX2009007071A (es) * 2007-01-03 2009-10-13 Cv Therapeutics Inc Elaboracion de imagen de perfusion del miocardio.
CA2958665C (en) 2007-10-19 2021-03-02 Sarcode Bioscience Inc. Compositions and methods for treatment of diabetic retinopathy
US20110064671A1 (en) 2008-03-10 2011-03-17 Cornell University Modulation of blood brain barrier permeability
WO2009128934A1 (en) * 2008-04-15 2009-10-22 Sarcode Corporation Topical lfa-1 antagonists for use in localized treatment of immune related disorders
US20090257957A1 (en) * 2008-04-15 2009-10-15 John Burnier Aerosolized LFA-1 antagonists for use in localized treatment of immune related disorders
US20090258069A1 (en) * 2008-04-15 2009-10-15 John Burnier Delivery of LFA-1 antagonists to the gastrointestinal system
WO2009139817A2 (en) 2008-04-15 2009-11-19 Sarcode Corporation Crystalline pharmaceutical and methods of preparation and use thereof
MX2011003168A (es) * 2008-09-29 2011-05-19 Gilead Sciences Inc Combinaciones de un agente de control de cantidad y un antagonista del receptor a-2-alfa para utilizarse en metodos de tomografia computarizada de detectores multiples.
US8378105B2 (en) 2009-10-21 2013-02-19 Sarcode Bioscience Inc. Crystalline pharmaceutical and methods of preparation and use thereof
CN101934559B (zh) * 2010-08-12 2013-04-17 中国电子科技集团公司第四十五研究所 具有压力调节机构的砂浆供给装置
EP3715345B8 (en) 2012-07-25 2024-05-29 Bausch + Lomb Ireland Limited Preparation of lfa-1 inhibitor

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4373097A (en) 1981-04-27 1983-02-08 Bioresearch S.R.L. Process for preparing adenosine derivatives of anti-inflammatory and analgesic activity
US5589467A (en) 1993-09-17 1996-12-31 Novo Nordisk A/S 2,5',N6-trisubstituted adenosine derivatives
WO1995033726A1 (en) * 1994-06-09 1995-12-14 Ss Pharmaceutical Co., Ltd. 4-quinolinone derivative or salt thereof
US5789416B1 (en) * 1996-08-27 1999-10-05 Cv Therapeutics Inc N6 mono heterocyclic substituted adenosine derivatives
GB9723590D0 (en) * 1997-11-08 1998-01-07 Glaxo Group Ltd Chemical compounds
GB9723566D0 (en) * 1997-11-08 1998-01-07 Glaxo Group Ltd Chemical compounds
US6294522B1 (en) * 1999-12-03 2001-09-25 Cv Therapeutics, Inc. N6 heterocyclic 8-modified adenosine derivatives
US6258793B1 (en) * 1999-12-03 2001-07-10 Cv Therapeutics, Inc. N6 heterocyclic 5′ modified adenosine derivatives
US6605597B1 (en) * 1999-12-03 2003-08-12 Cv Therapeutics, Inc. Partial or full A1agonists-N-6 heterocyclic 5′-thio substituted adenosine derivatives

Also Published As

Publication number Publication date
WO2001040243A3 (en) 2001-12-13
NO20015373L (no) 2001-11-29
AR029199A1 (es) 2003-06-18
BR0016126A (pt) 2002-08-06
CZ20013705A3 (cs) 2002-04-17
CN1378550A (zh) 2002-11-06
CA2389264A1 (en) 2001-06-07
KR100484988B1 (ko) 2005-04-22
NO20015373D0 (no) 2001-11-02
DK1233973T3 (da) 2004-02-16
AU761029B2 (en) 2003-05-29
DE60006576D1 (de) 2003-12-18
DE60006576T2 (de) 2004-09-16
AU4138701A (en) 2001-06-12
ES2208437T3 (es) 2004-06-16
ATE254133T1 (de) 2003-11-15
HK1047941A1 (zh) 2003-03-14
ZA200204380B (en) 2003-06-25
AU1811701A (en) 2001-06-12
IL145903A (en) 2006-04-10
US6605597B1 (en) 2003-08-12
PT1233973E (pt) 2004-02-27
MXPA01011113A (es) 2002-06-04
CA2389264C (en) 2007-03-06
JP2003516325A (ja) 2003-05-13
TR200103129T2 (tr) 2002-10-21
JP4021195B2 (ja) 2007-12-12
WO2001040246A1 (en) 2001-06-07
HUP0500455A2 (hu) 2005-08-29
EP1233973B1 (en) 2003-11-12
CN1152042C (zh) 2004-06-02
WO2001040243A2 (en) 2001-06-07
US20050054605A1 (en) 2005-03-10
AU7938301A (en) 2002-03-21
TWI249536B (en) 2006-02-21
EP1233973A1 (en) 2002-08-28
NZ514777A (en) 2004-01-30
KR20030032907A (ko) 2003-04-26

Similar Documents

Publication Publication Date Title
TR200301971T4 (tr) Kısmi veya tam A1 agonistler N6 hetorosiklik 5'-Tiyo ikameli adenosin türevleri
TR200201470T2 (tr) N6 heterosiklik 8-modifiye adenosin türevleri.
SE0003984D0 (sv) Adenosin A3-receptormodulatorer
NO20010446L (no) Substituert anilidforbindelser og metoder
TR200000015T2 (tr) Bileşikler ve metodlar
PT1019426E (pt) Agonistas e antagonistas do receptor de adenosina a1
EE04499B1 (et) A1-adenosiiniretseptori agonistid, nende valmistamismeetod ja kasutamine
DE69815378D1 (de) Adenosin a1-rezeptor agonisten
DE69825780D1 (de) Adenosin a1-rezeptor agonisten
TR199901721T2 (tr) Merkezi kanabinoid reseptör antagonistlerinin istah ayarlanmasinda kullanilmasi.
TR200102021T2 (tr) TWEAK ve TWEAK reseptörü antagonistleri ve bunların imünolojik bozuklukların iyileştirilmesi için kullanımları
PT951282E (pt) Prevenção e tratamento de doenças esqueléticas com agonistas e2 de protaglandinas selectivos do subtipo de receptores ep2
TR199700644T1 (tr) Serotonin-iliskili sistemler üzerinde etkiye sahip bilesikler.
PT901374E (pt) Tetra-hidropteridinas e piridilpiperazinas para o tratamento de disturbios neurologicos
PT745075E (pt) Derivados substituidos em 6 do acido micofenolico com actividade imunossupressora
DE68923048D1 (de) Alpha-Subeinheit des LFA-1-Leukocyt-Adhäsions-Rezeptors.
DK0463592T3 (da) 2,4- og 2,5-substituerede pyridin-N-oxider, fremgangsmåder til deres fremstilling samt deres anvendelse
BRPI0507776A (pt) métodos de modular a atividade de citocina; reagentes relacionados
TR200301062T2 (tr) Adenosin reseptörü antagonistleri ve bu antagonistlerin yapım ve kullanım yöntemleri
TR200001102T2 (tr) İkameli tetrahidropirimidinen türevleri, üretimleri ve kullanımları.
TR200003356T2 (tr) Kabergolin ve pramipeksol: yeni kullanım biçimleri ve birlikte kullanılmaları.
WO2001007471A3 (en) Cell cycle and proliferation proteins
ATE273390T1 (de) Säugertier edg-7 rezeptor homologen
DK1223930T3 (da) Behandling af dyskinesi
BR0015736A (pt) Derivados de adenosina modificados por n6 heterocìclico 8